Robot-assisted radical cholecystectomy for gallbladder cancer: A review

Weng Jiayi1*, Vishal G. Shelat2

1Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 2Department of General Surgery, Tan Tock Seng Hospital, Singapore

ABSTRACT

Background: Radical cholecystectomy (RC) is recommended for Gallbladder cancer (GbC) patients with resectable T1b or higher stage. Traditionally, open RC is preferred over minimally invasive approach. Robotic surgery is increasingly gaining popularity and there are reports of robotic RC (RRC) for GbC. RRC is still new and mostly performed in high-volume centers with access to robotic technology.

Aim: This study aims to review the current literature on the safety and feasibility of RRC for GbC.

Methods: We performed a systematic review of RRC for GbC using PubMed and Embase until December 2020. The primary endpoint was major complications, while the secondary endpoints were conversion to open, R0 resection, and early recurrence.

Results: Seven studies with 74 patients were included in the study. Overall, four patients (5.41%) required open conversion. Five out of 74 patients (6.76%) experienced post-operative complications. There was no post-operative mortality. Among the patients with surgical margins reported (n = 63), 61 patients had negative margins (96.8%) and only two patients had positive margins. Two-year survival outcomes were reported as 60.5–100%.

Relevance for Patients: This is the first review that summarizes the current evidence on RRC for GbC. The endpoints suggest that RRC is feasible and safe in selected patients and when done in experienced centers. Understanding the strengths and limitations of RRC compared to other established therapeutic options may potentially aid surgeons in formulating the optimal treatment plan for GbC patients.

1. Introduction

The gallbladder is the most common primary cancer site among the biliary tracts [1]. Globally, gallbladder cancer (GbC) accounts for 1.2% of all cancer diagnoses and 1.7% of all cancer deaths [2,3]. GbC has poor prognosis due to late presentation that often results in advanced stage at the time of diagnosis. In the US, only 20% of GbC are diagnosed early, 40% are diagnosed after spread to distant organs or lymph nodes and overall, 5-year survival rate of GbC is below 20% [4-7]. GbC is detected either incidentally (on histopathology) following cholecystectomy, or based on clinical findings and imaging before cholecystectomy. Incidental GbC following cholecystectomy is found in approximately 0.2–1.1% of all laparoscopic cholecystectomies [8], and has a better prognosis than non-incidentally-discovered GbC, provided the patient is staged and managed appropriately with R0 resection [9].

Simple cholecystectomy (laparoscopic or open) is curative in patients with Tis and T1a GbC. For patients with resectable T1b and above disease, radical cholecystectomy (RC) is advocated. RC consists of en bloc resection of the gallbladder, wedge resection of the liver, extrahepatic bile duct, and the regional lymph nodes including first-echelon (cystic duct and pericholedochal) and second-echelon lymph nodes (posterosuperior pancreaticoduodenal,
Traditionally, the open approach is preferred over minimally invasive approach due to the difficulty in achieving adequate lymphadenectomy, the complexity of liver resection, and the risk of gallbladder rupture leading to peritoneal metastases [12-17]. Recently, robotic surgery is increasingly popular [18]. The robotic approach has advantages such as filtration of hand tremor, seven degrees of freedom of wrist articulation, 3-dimensional (3D) stereoscopic images, and elimination of counterintuitive “fulcrum effect” of conventional laparoscopic surgery [19]. These advantages may facilitate precise dissection and intracorporeal suturing and thus make surgery safe. However, robotic RC (RRC) is still new and mostly performed in high volume centers but if safe and effective could potentially be replicated [20]. This study aims to review current literature on safety and feasibility of RRC for GbC.

2. Methods

2.1. Search strategy

We searched PubMed and Embase indexed human studies reporting on outcomes of RRC for GbC until December 2020. Search terms included “mini* invasive surg*”, “mini* access surg*”, “robotic surgery”, “robot assisted surgery”, “RC”, “extended cholecystectomy”, “port* lymphadenectomy”, “port* lymph node dissection”, “gallbladder adenocarcinoma”, “gallbladder carcinoma”, and “GbC”. There was no restriction on article type. The articles from both databases were combined and all duplicates were removed.

2.2. Selection criteria

Search did not yield any prospective randomized control trial. Retrospective single-arm case series or case-control studies were included. Elective RRC (performed when GbC was suspected before cholecystectomy) and completion RRC (performed as a completion treatment after a GbC was diagnosed following a simple cholecystectomy) were both included. We excluded articles that reported outcomes of robotic-assisted surgery for benign gallbladder diseases, metastases to gallbladder, or cholangiocarcinoma. We also excluded studies reporting on liver resection, isolated lymphadenectomy, or staging laparoscopy. Case reports, review articles, and guideline publications were excluded from the study. Case series that reported on robotic-assisted surgeries for GbC, but did not report the individual outcomes of RRC for GbC separately were also excluded from the analysis [21,22]. We performed manual search of the citations of the selected publications to include additional study. Abstracts of International HepatoPancreaticoBiliary Association (IHPBA) meetings (11th [Korea, 2014], 12th [Brazil, 2016] and 13th [Switzerland, 2018]) were browsed to identify additional study. If duplicate publications were reported from same institution, the most recent publication was included in the study.

2.3. Screening and data extraction

Of 227 potentially relevant publications identified through database and manual search, 206 publications were excluded by title and abstract screening, resulting in 21 articles which then underwent full-text screening. Any conflicts with regards to inclusion of the study was internally discussed between the two authors and consensus was achieved. Seven studies reporting 74 RRC were eligible for inclusion in this review (Figure 1).

3. Results

Seventy-four patients underwent RRC. Table 1 reports the demographic and clinical profile of patients included in this study. Table includes study period, number of patients, age and gender of patients, body mass index (BMI), conversion rate to open surgery, and number of completion and elective RRC. RRC was attempted as an elective procedure for a suspicion of GbC in 42 out of 54 (77.8%) patients and as a completion procedure for incidental GbC discovered after cholecystectomy in 12 out of 54 (22.2%) patients. The report of Pickens et al. (n = 20) did not mention if RRC was performed as index procedure or as completion following incidentally diagnosed GbC following simple cholecystectomy [20]. Overall, 4 patients (5.41%) required open conversion. Reasons for conversion include bile spillage (intraoperative gallbladder perforation) in one patient, frozen porta (nodes being adherent to the anterior surface of the portal vein) in one patient and elective conversion for excision of the extrahepatic biliary tree in two patients.

3.1. Operative outcomes

Table 2 shows the operative outcomes of RRC procedure. Table includes total blood loss, operation time, length of stay

**Figure 1.** Flow chart for study inclusion. Figure created with Review Manager 5.3.
Table 1. Demographic and clinical profile of patients treated by RRC

| Author, publication year | Country | Study period | Number | Age | Gender | BMI, kg/m² | Conversion to open RC (%) | Elective surgery/Completion surgery |
|--------------------------|---------|--------------|--------|-----|---------|------------|--------------------------|-----------------------------------|
| Byun et al., 2020 [19]   | South Korea | February 2018–April 2019 | 13     | 63.5±10.5<sup>a</sup> | 8 male, 5 female | 24.4±2.6<sup>a</sup> | Nil | 13 elective |
| Pickens et al., 2019 [20] | USA | January 2006–August 2018 | 20     | NR | NR | NR | Nil | NR |
| Goel et al., 2018 [24]   | India | July 2015–August 2018 | 27     | 54<sup>b</sup> (28–75)<sup>c</sup> | 9 male, 18 female | 24.4<sup>b</sup> (18.09–33.2)<sup>c</sup> | 4 (14.8%) | 2 completion, 25 elective |
| Shen et al., 2012 [25]   | China | March 2010–July 2011 | 5      | 57.4<sup>b</sup> (46–63)<sup>c</sup> | 2 male, 3 female | NR | Nil | 2 completion, 3 elective |
| Sinagra et al., 2017 [23] | Italy | April 2012–June 2014 | 3      | NR | NR | NR | Nil | 3 completion |
| Zeng et al., 2018 [26]   | Singapore | September 2015–June 2017 | 3      | NR | 1 male, 2 female | NR | Nil | 1 elective, 2 completion |
| Araujo et al., 2019 [27] | Brazil | NR | 3      | 45<sup>b</sup> (33–53)<sup>c</sup> | 1 male, 2 female | 30.9<sup>b</sup> (29.9–31.8)<sup>c</sup> | Nil | 3 completion |

Table 2. Operative outcomes of patients operated by RRC

| Author, publication year | Total blood loss, ml | Operation time, min | LOS, days | Morbidity (%) | Mortality | F/u duration, months |
|--------------------------|----------------------|---------------------|-----------|---------------|-----------|----------------------|
| Byun et al., 2020        | 270.8±297.9<sup>a</sup> | 187.7±34.6<sup>a</sup> | 6.6±1.7<sup>a</sup> | 2 (15.4%) | 90 day: Nil | NR |
| Pickens et al., 2019     | 150<sup>b</sup> (5–1200)<sup>c</sup> | 193<sup>b</sup> (112–447)<sup>c</sup> | 2.5<sup>b</sup> (0–6)<sup>c</sup> | 2 (10%) | 30 day: Nil | 12.8<sup>c</sup> (1–62)<sup>c</sup> |
| Goel et al., 2018        | 200<sup>b</sup> (20–700)<sup>c</sup> | 295<sup>b</sup> (200–710)<sup>c</sup> | 4<sup>b</sup> (2–12)<sup>c</sup> | 1 (3.7%) | 90 day: Nil | 9<sup>c</sup> (1–46)<sup>c</sup> |
| Shen et al., 2011        | 210<sup>b</sup> (50–400)<sup>c</sup> | 200<sup>b</sup> (120–300)<sup>c</sup> | 7.4<sup>b</sup> (7–8)<sup>c</sup> | Nil | Nil in-hospital mortality | 11<sup>c</sup> (1–17)<sup>c</sup> |
| Sinagra et al., 2017     | 150<sup>b</sup> (100–350)<sup>c</sup> | 300<sup>b</sup> (240–310)<sup>c</sup> | 6<sup>b</sup> (5–7)<sup>c</sup> | Nil | Nil in-hospital mortality | 24<sup>c</sup> (18–32)<sup>c</sup> |
| Zeng et al., 2018        | 200<sup>b</sup> (50–700)<sup>c</sup> | 360<sup>b</sup> (220–530)<sup>c</sup> | 3<sup>b</sup> (3–4)<sup>c</sup> | Nil | Nil in-hospital mortality | NR |
| Araujo et al., 2019      | 183<sup>b</sup> (50–300)<sup>c</sup> | 392<sup>b</sup> (380–410)<sup>c</sup> | 3<sup>b</sup> | Nil | 90 day: | 3<sup>c</sup> |

a: mean, b: median, c: range, BMI: body mass index, RC: Radical cholecystectomy, RRC: Robotic radical cholecystectomy, NR: not reported

(LOS), morbidity, mortality, and follow-up duration. Mean total blood loss was 194.8 ml (range: 5–1200 ml), mean operation duration was 275 min (range: 112–710 min), and mean LOS was 4.65 days (range: 0–12 days). Overall, 5 out of 74 patients (6.76%) experienced post-operative morbidity. There was no post-operative mortality. The mean follow-up duration was 12.0 months (range: 1–62 months).

3.2. Oncologic outcomes

Table 3 shows the oncologic outcomes of GbC patients operated by RRC. Table includes survival outcomes, cancer staging, number of lymph nodes harvested, rate of R0 resection, and recurrence during follow-up. Long-term survival outcomes were reported in four studies [20,23-25]. As for cancer staging, T stage was reported for 54 patients. 15 patients (27.8%) had T1b or less advanced stage, 38 patients (70.4%) had T2 or more advanced stage, while the remaining 1 patient had Tx stage. N stage was reported for 41 patients, out of which 2 patients had N1 stage (4.88%). M stage was reported for 54 patients, out of which 1 patient had metastatic GbC (1.85%). Mean number of lymph nodes resected was 9.07 (range: 1–22). Across the sven studies, surgical margins were reported in 63 patients, out of which R0 resection was achieved in 61 patients (96.8%). Out of the three studies that reported recurrence during follow-up, two patients developed bilobar liver metastases [24], and one patient had tumor occurrence that resulted in mortality [25].

4. Discussion

GbC has dismal survival outcomes due to delayed presentation, aggressive tumor biology, and lack of effective chemotherapy. RC is the only curative option, and it is advocated either as a completion surgery after GbC was diagnosed following a
simple cholecystectomy or as an elective surgery when GbC was diagnosed or suspected before cholecystectomy. With advances in robotic technology, RRC is reported by high-volume centers with access to robotic technology. This review confirms that in patients with GbC, RRC is safe and feasible with acceptable peri-operative outcomes.

The optimal surgical management of GbC is guided by TNM classification system [1,2]. Simple cholecystectomy by either open or laparoscopic technique [3,4] is adequate for T0 or T1a GbC with 5-year survival rate 95%–100% [7]. Open RC is considered the gold standard for stage T1b and beyond operable patients with GbC. The open approach is preferred over the laparoscopic approach due to concerns for port-site metastases, the difficulty in achieving adequate lymphadenectomy, the complexity of liver resection, and the risk of gallbladder rupture leading to disseminated peritoneal metastases [12-17]. Minimal access surgery is proven to improve peri-operative outcomes by reducing post-operative pain, wound complications and facilitates early recovery. With advances in technology and surgical instrumentation, minimal access surgery is increasingly adopted in gastrointestinal oncology including major hepatobiliary and pancreatic surgery. Due to the paucity of GbC in Western world, lack of screening programs for early diagnosis of GbC, and relatively slow adoption of minimal access surgery for complex biliary procedures, there is a lack of evidence supporting safety and feasibility of minimal access RC. Increased prevalence of GbC in developing economies like Bolivia, Chile, India, and Thailand where accessibility and affordability of robotic surgery is limited is contributory to the paucity of high-quality clinical data showing benefits of RRC. Despite such sporadic disparities, increased availability, accessibility, and adoption of robotic technology have fuelled the enthusiasm in minimal access complex biliary surgery as robotic platform reduces technical challenges associated with laparoscopic surgery. Thus, the past decade has witnessed reports of GbC treated by RRC. At the present time, affordability remains the main challenge for many surgical units to embrace robotic surgery. Healthcare systems largely follow utilitarian ethics, and thus without strong evidence of benefit, it is not rational to justify the extra cost incurred for using robotic platform for the procedures that can be performed by laparoscopic techniques. As for example in Singapore, an estimated additional cost of SGD 5000 is billed to patient for using robotic platform.

Robotic surgery is increasingly used in a number of surgical procedures in recent years, notably complex hepato-pancreato-biliary surgeries such as major hepatectomy [28] and pancreatoduodenectomies [29-31]. Advancements in the field of robotic technology have overcome many limitations associated with laparoscopy, prompting more surgeons to consider using robotic surgery in treatment of GbC [26]. Although there are several reports of good outcomes for laparoscopic RC, these are limited to a few highly specialized centers [32-35]. GbC is typically diagnosed at advanced stage and has a high possibility of lymphatic metastasis [2,36]. Adequate lymphadenectomy is essential to improve survival outcomes [37-39]. Studies have shown that the resection and histologic evaluation of at least six lymph nodes are required to improve the risk stratification of GbC [15,38-40] and the range of lymphadenectomy should include the posterosuperior pancreatic head lymph nodes along the hepatoduodenal ligament and the hepatic artery [41-43]. Studies included in this review [20] showed that RRC had significantly greater lymph node harvest compared to laparoscopic RC. Mean number of lymph nodes resected was 10, which exceeded the criteria of at least six lymph nodes.

**Table 3. Oncologic outcomes of patients operated by RRC**

| Author, publication year | Survival | T stage | N stage | M stage | Number of LN harvested | R0 resection | Recurrence |
|--------------------------|----------|---------|---------|---------|------------------------|--------------|------------|
| Byun et al., 2020        | NR       | T0-T1: 5 T2/T3: 8 | NR      | M0:13 | 7.2±3.1b | 13 (100%) | NR |
| Pickens et al., 2019     | 1 year survival – 70.6% 2 year survival – 60.5% | NR | NR | NR | 5b (2–15)b | 12 out of 14 (85.7%) | NR |
| Goel et al., 2018        | DFS at 9 months – 92.6% | Tx: 1 | N0: 27 | M0: 27 | 10b (2–21)b | 27 (100%) | 2 (7.41%) |
| Shen et al., 2011        | 1 year survival – 80% | T2: 2 T3: 3 | N0: 5 | M0: 5 | 9b (3–11)b | NR | 1 (20%) |
| Sinagra et al., 2017     | 2 year survival – 100% | T1b: 3 | N0: 2 N1: 1 | M0: 3 | 21b (20–22)b | 3 (100%) | Nil |
| Zeng et al., 2018        | NR       | T2: 1 T3: 2 | N0: 2 N1: 1 | M0: 2 M1: 1 | 7b (1–11)b | 3 (100%) | NR |
| Araujo et al., 2019      | NR       | T1b: 3 | N0: 3 | M0: 3 | 4.3b (3–6)b | 3 (100%) | NR |

a: mean, b: median, c: range, LOS: length of stay, F/u: follow-up, DFS: disease-free survival, OS: overall survival, LN: lymph nodes, NR: not reported, RRC: Robotic radical cholecystectomy.

DOI: http://dx.doi.org/10.18053/jctres.08.202202.001
and demonstrated that adequate and safe lymphadenectomy can be performed through the robotic approach. To achieve sufficient lymphadenectomy in hepatoduodenal ligament territory, critical structures such as the hepatic artery, portal vein, and common bile duct must be fully skeletonized. This is often technically challenging to perform with conventional straight and rigid laparoscopic instruments and risks rupturing the gallbladder causing peritoneal metastases [44]. Compared to the traditional rigid laparoscopic instruments [26], the flexibility of the robotic arms offers better access to the operative field and improved dexterity, allowing surgeons to perform the hilar dissection more easily. Robotic technology allows precise dissection, stable retraction, stereoscopic image with depth perception as well as facilitates intracorporeal suturing and this makes dissection safe and elegant. It is important to note that despite these promising outcomes, one of the non-elective conversion to open RC reported by Goel et al. was due to lymph nodes being adherent to the anterior surface of the portal vein. This shows that achieving lymphadenectomy still prove challenging in robotic surgery and endorses that despite using robotic platform, in some patients, surgery will remain challenging. In addition, our review reports two open conversions for hepaticojejunostomy reconstruction. It is not entirely clear if there were competing reasons for open conversion, as we would assume that robotic platform facilitates bilio-enteric reconstruction. In our opinion learning curve and considerations of patient safety probably contributed to open conversions.

Current studies on the use of robotic surgery for GbC, although limited, show promising perioperative outcomes. This is well supported by evidence presented in this review. Compared to open RC, RRC was associated with shorter LOS, lesser intraoperative blood loss, and post-operative morbidity [20,24]. The poorer perioperative outcomes of conventional open RC can be attributed to the inverted L-incision or the right subcostal incision transecting the rectus abdominis muscle. These incisions lead to post-operative pain, pulmonary complications related to pain and splinting of the diaphragm, and longer time to recovery [19]. Intuitively it is possible that RRC benefits patients from reduced pleuropulmonary and wound morbidity; and thus, adjuvant chemotherapy can be started early, with potential oncologic benefits. Studies in this review also demonstrated that RRC has high lymph node yield with comparable overall survival and R0 resection to that of open RC [20,24]. Goel et al. showed that the recurrence rate was much lower after RRC (7.41%) than after open RC (17.1%) [24]. This could be due to selection bias inherent to retrospective studies. This review is unable to conclude if RRC has oncologic advantage over open RC and more evidence is needed, preferably by prospective studies including more patients. In addition, port-site metastases are an important complication of GbC surgery. There is insufficient data if RRC has an equal or reduced risk of port-site metastases.

This is the first review that summarizes the current evidence on RRC and heterogeneity in reporting outcomes is evident, and thus, generalizations cannot be made. Majority of studies did not report long-term oncologic outcomes, and thus benefits of robotic platform to enhance survival outcomes remain to be shown. We foresee that with more accessibility and affordability of robotic technology, more evidence will follow. In conclusion, RRC is safe and feasible, and more evidence is needed with regard to oncologic outcomes of RRC.

Conflict of interest

The authors declare no conflicts of interest.

References

[1] Hundal R, Shaffer EA. Gallbladder Cancer: Epidemiology and Outcome. Clin Epidemiol 2014;6:99-109.
[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jamal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2018;68:394-424.
[3] Egner JR. Abeloff’s Clinical Oncology. JAMA 2010;303:1097-97.
[4] SEER Cancer Statistics Review, 1975-2014. National Cancer Institute; 2017. https://seer.cancer.gov/csr/1975_2014/. [Last accessed on 2021 Dec 10].
[5] SEER*Explorer: An interactive website for SEER Cancer statistics. Surveillance Research Program, National Cancer Institute; 2020. https://seer.cancer.gov/explorer/. [Last accessed on 2021 Dec 10].
[6] Cancer Facts and Figures 2018. American Cancer Society; 2018. Available from: https://www.cancer.org/cancer/gallbladder-cancer/about/key-statistics.html. [Last accessed on 2021 Dec 10].
[7] Henley SJ, Weir HK, Jim MA, Watson M, Richardson LC. Gallbladder Cancer Incidence and Mortality, United States 1999-2011. Cancer Epidemiol Biomarkers Prev 2015;24:1319-26.
[8] Pitt SC, Jin LX, Hall BL, Strasberg SM, Pitt HA. Incidental Gallbladder Cancer at Cholecystectomy: When should the Surgeon be Suspicious? Ann Surg 2014;260:128-33.
[9] Smith GC, Parks RW, Madhavan KK, Garden OJ. A 10-year Experience in the Management of Gallbladder Cancer. HPB (Oxford) 2003;5:159-66.
[10] Shirai Y, Yoshida K, Tsukada K, Ohtani T, Muto T. Identification of the Regional Lymphatic System of the Gallbladder by Vital Staining. Br J Surg 1992;79:659-62.
[11] Shirai Y, Wakai T, Hatakeyama K. Radical Lymph Node Dissection for Gallbladder Cancer: Indications and Limitations. Surg Oncol Clin North Am 2007;16:221-32.
[12] Nasiri S, Gafuri A, Karamnejad M, Farshidfar F. Four Port-site Recurrences of Gall Bladder Cancer after Laparoscopic Cholecystectomy. ANZ J Surg 2009;79:75-6.
[13] Aloia TA, Jáurefe N, Javel M, Maithel SK, Roa JC, Adsay V,
et al. Gallbladder Cancer: Expert Consensus Statement. HPB (Oxford) 2015;17:681-90.

[14] Choi S, Han HJ, Kim C, Kim WB, Song TJ, Suh SO, et al. Fourteen Year Surgical Experience of Gallbladder Cancer: Validity of Curative Resection Affecting Survival. Hepatogastroenterology 2012;59:36-41.

[15] Ito H, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P, et al. Accurate Staging for Gallbladder Cancer: Implications for Surgical Therapy and Pathological Assessment. Ann Surg 2011;254:320-5.

[16] Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for the Management of Biliary Tract and Ampullary Carcinomas: Surgical Treatment. J Hepatobiliary Pancreat Surg 2008;15:41-54.

[17] Dixon E, Vollmer CM Jr., Sahajpal A, Cattral M, Grant D, Doig C, et al. An Aggressive Surgical Approach Leads to Improved Survival in Patients with Gallbladder Cancer: A 12-Year Study at a North American Center. Ann Surg 2005;241:385-94.

[18] Sheetz KH, Claffin J, Dimick JB. Trends in the Adoption of Robotic Surgery for Common Surgical Procedures. JAMA Network Open 2020;3:e1918911.

[19] Byun Y, Choi YJ, Kang JS, Han Y, Kim H, Kwon W, et al. Early Outcomes of Robotic Extended Cholecystectomy for the Treatment of Gallbladder Cancer. J Hepatobiliary Pancreat Sci 2020;27:324-30.

[20] Pickens RC, Isenberg EE, Sulzer JK, Murphy K, Martinie JB, Iannitti DA, et al. Robotic Radical Cholecystectomy for Gallbladder Cancer at a High-volume Minimally Invasive Center. HPB 2019;21:S33.

[21] Sucandy I, Schlosser S, Bourdeau T, Spence J, Attili A, Ross S, et al. Robotic Hepatectomy for Benign and Malignant Liver Tumors. J Robot Surg 2020;14:75-80.

[22] Liu QD, Chen JZ, Xu XY, Zhang T, Zhou NX. Incidence of Port-site Metastasis after Undergoing Robotic Surgery for Biliary Malignancies. World J Gastroenterol 2012;18:5695-701.

[23] Sinagra E, Garritano S, Iacopinelli SM, Messina M, Raimondo D, Rossi F, et al. Minimally Invasive Surgical Approach for Radicalization of Incidental Post-cholecystectomy Gallbladder Carcinoma: Safety, Feasibility and Outcomes. Minim Invasive Ther Allied Technol 2018;27:217-20.

[24] Goel M, Khobragade K, Patkar S, Kanetkar A, Kurunkar S. Robotic Surgery for Gallbladder Cancer: Operative Technique and Early Outcomes. J Surg Oncol 2019;119:958-63.

[25] Shen BY, Zhan Q, Deng XX, Bo H, Liu Q, Peng CH, et al. Radical Resection of Gallbladder Cancer: Could it be Robotic? Surg Endosc 2012;26:3245-50.

[26] Zeng G, Teo NZ, Goh BK. Short-term Outcomes of Minimally Invasive Surgery for Patients Presenting with Suspected Gallbladder Cancer: Report of 8 Cases. J Minim Access Surg 2018;15:109-14.

[27] Araujo RL, de Sanctis MA, Coelho TR, Felippe FE, Burgardt D, Wohrath DR. Robotic surgery as an alternative approach for reoperation of incidental gallbladder cancer. J Gastrointest Cancer 2020;51:332-4.

[28] Chen PD, Wu CY, Hu RH, Chen CN, Yuan RH, Liang JT, et al. Robotic Major Hepatectomy: Is there a Learning Curve? Surgery 2017;161:642-9.

[29] Kim H, Kim JR, Han Y, Kwon W, Kim SW, Jang YJ. Early Experience of Laparoscopic and Robotic Hybrid Pancreatoduodenectomy. Int J Med Robot 2017;13:1814.

[30] Nguyen KT, Gamblin TC, Geller DA. World Review of Laparoscopic Liver Resection-2,804 Patients. Ann Surg 2009;250:831-41.

[31] Kornaropoulos M, Moris D, Beal EW, Makris MC, Mitrousias A, Petrou A, et al. Total Robotic Pancreatoduodenectomy: A Systematic Review of the Literature. Surg Endosc 2017;31:4382-92.

[32] Kim S, Yoon YS, Han HS, Cho JY, Choi YR. Laparoscopic Extended Cholecystectomy for T3 Gallbladder Cancer. Surg Endosc 2018;32:2984-5.

[33] Zhao X, Li XY, Ji W. Laparoscopic Versus Open Treatment of Gallbladder Cancer: A Systematic Review and Meta-analysis. J Minim Access Surg 2018;14:185-91.

[34] Yoon YS, Han HS, Cho JY, Choi YR, Lee W, Jang YJ, et al. Is Laparoscopy Contraindicated for Gallbladder Cancer? A 10-Year Prospective Cohort Study. J Am Coll Surg 2015;221:847-53.

[35] Castro CM, Santibañez SP, Rivas TC, Cassis NJ. Totally Laparoscopic Radical Resection of Gallbladder Cancer: Technical Aspects and Long-Term Results. World J Surg 2018;42:2592-8.

[36] Pilgrim C, Usatoff V, Evans PM. A Review of the Surgical Strategies for the Management of Gallbladder Carcinoma Based on T Stage and Growth Type of the Tumour. Eur J Surg Oncol 2009;35:903-7.

[37] Mishra PK, Saluja SS, Prithiviraj N, Varshney V, Goel N, Patil N. Predictors of Curative Resection and Long Term Survival of Gallbladder Cancer a Retrospective Analysis. Am J Surg 2017;214:278-86.

[38] Fan DX, Xu RW, Li YC, Zhao BQ, Sun MY. Impact of the Number of Examined Lymph Nodes on Outcomes in Patients with Lymph Node-negative Gallbladder Carcinoma. World J Gastroenterol 2018;24:2866-92.

[39] Liu GJ, Li XY, Chen YX, Sun MY. Impact of the Number of Examined Lymph Nodes on Outcomes in Patients with Lymph Node-negative Gallbladder Carcinoma. World J Gastroenterol 2018;24:2866-92.

[40] Negi SS, Singh A, Chaudhary A. Lymph Nodal Involvement as Prognostic Factor in Gallbladder Cancer: Location, DOI: http://dx.doi.org/10.18053/jctres.08.202202.001
Count or Ratio? J Gastrointest Surg 2011;15:1017-25.

[41] Sakata J, Kobayashi T, Tajima Y, Ohashi T, Hirose Y, Takano K, et al. Relevance of Dissection of the Posterior Superior Pancreaticoduodenal Lymph Nodes in Gallbladder Carcinoma. Ann Surg Oncol 2017;24:2474-81.

[42] Vega EA, Yamashita S, Chun YS, Kim M, Fleming JB, Katz MH, et al. Effective Laparoscopic Management Lymph Node Dissection for Gallbladder Cancer. Ann Surg Oncol 2017;24:1852.

[43] Kishi Y, Nara S, Esaki M, Hiraoka N, Shimada K. Extent of Lymph Node Dissection in Patients with Gallbladder Cancer. Br J Surg 2018;105:1658-64.

[44] Georgakis GV, Novak S, Bartlett DL, Zureikat AH, Zeh H, Hogg ME. The Emerging Role of Minimally-invasive Surgery for Gallbladder Cancer: A Comparison to Open Surgery. Conn Med 2018;82:211-6.

Publisher’s note

Wioce Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

DOI: http://dx.doi.org/10.18053/jctres.08.202202.001